{"filing":{"accession_number":"0001437749-26-019262","cik":"0001001316","ticker":"TGTX","company_name":"TG THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"tgtx20260602_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/tgtx20260602_8k.htm"},"events":[{"id":7222,"run_id":6336,"accession_number":"0001437749-26-019262","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"TG Therapeutics disclosed positive Phase 1 clinical trial data for a subcutaneous formulation of ublituximab (BRIUMVI®) in relapsing multiple sclerosis. While clinical trial results can be material to investors assessing pipeline value and competitive positioning, this disclosure does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The positive PK/PD and safety data would reasonably affect an investor's assessment of the company's drug development prospects, warranting classification as other_material.","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4049,"accession_number":"0001437749-26-019262","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"TG Therapeutics disclosed positive Phase 1 clinical trial data for a subcutaneous formulation of ublituximab (BRIUMVI®) in relapsing multiple sclerosis. While clinical trial results can be material to investors assessing pipeline value and competitive positioning, this disclosure does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The positive PK/PD and safety data would reasonably affect an investor's assessment of the company's drug development prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:37.308050+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4049,"accession_number":"0001437749-26-019262","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"TG Therapeutics disclosed positive Phase 1 clinical trial data for a subcutaneous formulation of ublituximab (BRIUMVI®) in relapsing multiple sclerosis. While clinical trial results can be material to investors assessing pipeline value and competitive positioning, this disclosure does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The positive PK/PD and safety data would reasonably affect an investor's assessment of the company's drug development prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:37.308050+00:00","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-06-03"}]}